Compare STRIDES PHARMA SCIENCE with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs AJANTA PHARMA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE AJANTA PHARMA STRIDES PHARMA SCIENCE/
AJANTA PHARMA
 
P/E (TTM) x 14.2 21.4 66.3% View Chart
P/BV x 0.8 3.8 22.2% View Chart
Dividend Yield % 0.6 0.9 62.0%  

Financials

 STRIDES PHARMA SCIENCE   AJANTA PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
AJANTA PHARMA
Mar-19
STRIDES PHARMA SCIENCE/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1471,422 80.7%   
Low Rs642898 71.5%   
Sales per share (Unadj.) Rs317.2233.5 135.9%  
Earnings per share (Unadj.) Rs7.844.0 17.8%  
Cash flow per share (Unadj.) Rs25.152.2 48.0%  
Dividends per share (Unadj.) Rs2.009.00 22.2%  
Dividend yield (eoy) %0.20.8 28.8%  
Book value per share (Unadj.) Rs274.3255.1 107.5%  
Shares outstanding (eoy) m89.5088.02 101.7%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x2.85.0 56.8%   
Avg P/E ratio x114.026.4 432.3%  
P/CF ratio (eoy) x35.722.2 160.5%  
Price / Book Value ratio x3.34.5 71.7%  
Dividend payout %25.520.5 124.5%   
Avg Mkt Cap Rs m80,058102,081 78.4%   
No. of employees `0002.56.8 36.9%   
Total wages/salary Rs m4,3414,307 100.8%   
Avg. sales/employee Rs Th11,325.83,022.6 374.7%   
Avg. wages/employee Rs Th1,731.4633.4 273.3%   
Avg. net profit/employee Rs Th280.1569.1 49.2%   
INCOME DATA
Net Sales Rs m28,39420,554 138.1%  
Other income Rs m941211 446.2%   
Total revenues Rs m29,33420,765 141.3%   
Gross profit Rs m3,9655,664 70.0%  
Depreciation Rs m1,540721 213.7%   
Interest Rs m1,96212 16,917.2%   
Profit before tax Rs m1,4035,143 27.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m971,273 7.6%   
Profit after tax Rs m7023,870 18.1%  
Gross profit margin %14.027.6 50.7%  
Effective tax rate %6.924.8 28.0%   
Net profit margin %2.518.8 13.1%  
BALANCE SHEET DATA
Current assets Rs m24,83611,812 210.3%   
Current liabilities Rs m18,9933,776 502.9%   
Net working cap to sales %20.639.1 52.6%  
Current ratio x1.33.1 41.8%  
Inventory Days Days7177 91.7%  
Debtors Days Days11382 139.0%  
Net fixed assets Rs m34,28914,398 238.1%   
Share capital Rs m895175 510.3%   
"Free" reserves Rs m23,65122,277 106.2%   
Net worth Rs m24,54622,452 109.3%   
Long term debt Rs m15,5137 235,048.5%   
Total assets Rs m65,43726,962 242.7%  
Interest coverage x1.7444.3 0.4%   
Debt to equity ratio x0.60 215,001.1%  
Sales to assets ratio x0.40.8 56.9%   
Return on assets %4.114.4 28.3%  
Return on equity %2.917.2 16.6%  
Return on capital %6.923.0 30.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69710,682 147.0%   
Fx outflow Rs m7352,102 35.0%   
Net fx Rs m14,9628,580 174.4%   
CASH FLOW
From Operations Rs m1,8713,748 49.9%  
From Investments Rs m5,826-2,228 -261.5%  
From Financial Activity Rs m-10,157-1,475 688.8%  
Net Cashflow Rs m-2,61545 -5,785.2%  

Share Holding

Indian Promoters % 27.7 73.8 37.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 1.6 2,438.7%  
FIIs % 8.6 7.6 113.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 17.0 152.4%  
Shareholders   56,241 20,968 268.2%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   GLENMARK PHARMA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  BIOCON   UNICHEM LAB  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Higher; Energy & Realty Stocks Lead(09:30 am)

Asian share markets are higher today as Britain and the EU made headway on a Brexit deal ahead of a leaders' summit.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Oct 16, 2019 10:27 AM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS